Table 1.

50% Effective dose of oHSV in GBM and non-GBM cell lines

MOI (x10−3), 95% Confidence intervals
rHSVQNG34
ED50R-SeqED50R-Seq
U25122.67 – 47.630.89472.620 – 5.4360.8728
U2OS15.11 – 41.570.75167.172 – 15.900.8516
G9Rluc34.63 – 70.440.91734.827 – 7.9220.9587
G309.439 – 16.870.93921.962 – 3.1500.9588
G8325.08 – 54.510.90284.424 – 9.7370.8810
G32617.87 – 43.330.88503.564 – 7.0580.9237
G52886.39 – 270.70.697326.66 – 64.310.8706
  • NOTE: Enhanced glioma cytotoxicity effect with GADD34-encoding γ134.5-null NG34 versus original γ134.5-null rHSVQ virus. Intracellular ATP was measured 3 days after oHSV infection with either rHSVQ or NG34 or rQNestin34.5 in GBM (U251, G9Rluc and G30) and non-GBM (U2OS) cells at 20,000 cells per a well of 96-well plates for cell viability assay. Data with three replicates were normalized with maximum and minimum values before calculating ranges of 50% effective doses (ED50) and values of R2 at 95% confidence intervals. These plots with nonlinear dose–response curves are also provided in Supplementary Fig. S1.